- Home
- PNTG vs KALV Comparison
PNTG vs KALV Comparison
Compare PNTG & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PNTG
- KALV
- Stock Information
- Founded
- PNTG 2019
- KALV N/A
- Country
- PNTG United States
- KALV United States
- Employees
- PNTG N/A
- KALV N/A
- Industry
- PNTG Medical/Nursing Services
- KALV Biotechnology: Pharmaceutical Preparations
- Sector
- PNTG Health Care
- KALV Health Care
- Exchange
- PNTG Nasdaq
- KALV Nasdaq
- Market Cap
- PNTG 829.8M
- KALV 796.4M
- IPO Year
- PNTG N/A
- KALV N/A
- Fundamental
- Price
- PNTG $24.55
- KALV $13.64
- Analyst Decision
- PNTG Buy
- KALV Strong Buy
- Analyst Count
- PNTG 6
- KALV 8
- Target Price
- PNTG $35.00
- KALV $26.43
- AVG Volume (30 Days)
- PNTG 362.9K
- KALV 1.0M
- Earning Date
- PNTG 11-05-2025
- KALV 09-11-2025
- Dividend Yield
- PNTG N/A
- KALV N/A
- EPS Growth
- PNTG 20.56
- KALV N/A
- EPS
- PNTG 0.77
- KALV N/A
- Revenue
- PNTG $798,923,000.00
- KALV $1,426,000.00
- Revenue This Year
- PNTG $28.29
- KALV N/A
- Revenue Next Year
- PNTG $11.61
- KALV $213.43
- P/E Ratio
- PNTG $32.65
- KALV N/A
- Revenue Growth
- PNTG 30.58
- KALV N/A
- 52 Week Low
- PNTG $21.18
- KALV $7.30
- 52 Week High
- PNTG $37.13
- KALV $17.28
- Technical
- Relative Strength Index (RSI)
- PNTG 48.52
- KALV 52.46
- Support Level
- PNTG $23.68
- KALV $13.26
- Resistance Level
- PNTG $26.11
- KALV $17.28
- Average True Range (ATR)
- PNTG 0.79
- KALV 0.91
- MACD
- PNTG 0.03
- KALV -0.86
- Stochastic Oscillator
- PNTG 37.40
- KALV 79.20
About PNTG The Pennant Group Inc.
Pennant Group Inc is engaged in providing healthcare services to patients of all ages, including the growing senior population, in the United States. It operates in multiple lines of business including home health, hospice, and senior living which includes the company's assisted living, independent living, and memory care communities across Arizona, California, Colorado, Idaho, Montana, Nevada, Oklahoma, Oregon, Texas, Utah, Washington, Wisconsin, and Wyoming. The company generates majority of its revenue from home health and hospice services segment, which includes its home health, hospice and home care businesses.
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.